Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2013

Aug 10, 2013

151_ip_2013-08-10_33a0535e-f348-4631-a54d-85cd016a1e98.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

H1 2013Innovation on t ack track efficiency

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties uncertainties. The forward forward-lo contained herein represent the judgemen the date of this presentation. Such statements are neither promises nor gua subject to a variety of risks and uncert which are beyond our control, and wh ntation containsolve a number ofoking statements nt of Evotec as offorward-looking arantees, but are tainties, many of hich could cause

actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Welcome from thee Evotec management team

H1 2013

Agenda

Highlights H1 2013

  • Strategy on innovation e efficiency
  • Financial performance & & outlook

1

2

3

Innovation efficienncy strategy on track

State of play – H1 2013

  • Revenues excluding milestones, upfronts and licences i ncreased by 6% compared to H1 2012 on a like-for-like basis
  • H1 2013 revenues of € 36 7 m (2012: € 42 0 m) lower 36.7 42.0 – r revenues due to expected lower milestones
  • € 4.4 m operating loss due to accelerated spending for i nnovation and low milestone revenues in H1 2013

EVT Execute

  • Three-year extension of drug discovery alliance with Ge nentech
  • Collaboration with Dow AgroSciences on Cellular Target t Profiling®
  • Extension of Active Biotech collaboration1)
  • Strategic expansion of compound management capabili ty on US East Coast

EVT Integrate

Good progress in integrated alliances highlighted by mile estone achievement with Boehringer Ingelheim

EVT Innovate

  • Significant clinical data points ahead in 2013/2014/2015 5
  • New alliance with Harvard University: TargetPGB (Peptid doglycan Biosynthesis)
  • O l ll b ti ith B lf I tit t T tKDM 4 Oncology collaboration with Belfer Institute: Target (L i D th l Lysine Demethylases)
  • Broad open innovation alliance started with Yale Univers sity

Guidance confirmeed

Financial summary H1 20 13 & Outlook for 2013

R
h
t
e
e
n
e
g
r
o
v
u
w
l
d
i
e
x
c
u
n
g
i
l
t
m
e
s
o
n
e
s
,
f
d
t
u
p
r
o
n
s
a
n
l
i
c
e
n
c
e
s		 R
d
d
b
1
3
%
€
3
6
l
d
i
i
l
f
t
7
t
t
e
e
n
e
s
e
c
r
e
a
s
e
o
m
e
c
n
g
m
e
s
o
n
e
s
p
r
o
n
s
v
u
y
y
;
x
u
u

,
d
l
i
l
d
h
i
d
b
6
%
h
i
d
t
a
n
c
e
n
c
e
s
r
e
v
e
n
u
e
s
w
w
o
u
a
v
e
n
c
r
e
a
s
e
y
o
v
e
r
e
s
a
m
e
p
e
r
o
,
f
h
i
l
i
k
f
l
i
k
b
i
t
o
e
p
r
e
o
s
e
a
r
o
n
a
a
e
o
r-
e
a
s
s
v
u
y
-
S
b
l
l
i
i
d
i
i
i
€
6
1
t
t
t
t
5
a
e
q
u
y
p
o
s
o
n
a
a
m

H
i
h
d
b
l
i
i
6
%
t
t
t
t
7
7
g
a
n
s
a
e
e
q
u
y
r
a
a
o
a
f
f
I
t
t
t
t
n
e
s
m
e
n
s
o
r
v
f
i
i
l
t
r
s
n
-c
a
s
s
-
t
t
a
r
g
e
s		 &
f
€
f
f
I
d
R
D
4
8
i
t
d
i
t
h
i
l
d
n
c
r
e
a
s
e
e
x
p
e
n
s
e
e
s
o
m
n
v
e
s
e
n
e
e
s
o

C
X
d
T
X
i
i
i
i
G
P
C
R
d
k
i
l
f
h
l
i
t
t
t
t
t
t
r
e
a
r
g
e
u
a
n
n
a
v
e
s
a
n
n
a
s
e
p
a
o
r
m
e
c
n
o
o
g
e
s
,
G
i
d
u
a
n
c
e
f
f
2
0
1
3
o
r
f
i
d
c
o
n
r
m
e		 O
d
b
k
d
i
l
t
t
i
t
i
i
H
2
2
0
1
3
i
d
i
t
r
e
r
o
o
a
n
m
e
s
o
n
n
e
o
p
p
o
r
n
e
s
n
n
c
a
e
u

f
€
9
0
1
0
0
f
2
0
1
3
r
e
v
e
n
u
e
s
o
m
o
r
-
I
i
f
l
l-
f
i
b
i
l
i
d
h
t
t
t
t
t
n
c
r
e
a
s
n
g
u
y
e
a
r
p
r
o
a
y
u
e
o
r
e
v
e
n
u
e
g
r
o
w

1
)
d
d
i
l
t
t
t
a
n
e
p
e
c
e
m
e
s
o
n
e
p
a
m
e
n
s
x
y

Agenda

  • Highlights H1 2013
  • Strategy on innovation n efficiency
  • Financial performance & & outlook

Addressing the inn novation challenge

Innovation efficiency

Stand-alone Execugenerates solid gr ute business rowth in H1 2013

Comprehensive drug disco overy platform – "EVO Apps"

Closure of chemisstry operations in India

Background and implicati ions

Background g

  • Thane (India) lease expires in June 2014 with no option to extend
  • Growing customer requirement for chemistry to be aligned with their R&D operations in Europe and the US
  • Rate of inflation and other costs are expected to rise in India in the next the years – efficiency and cost advantage of producing in India will decrease

Next steps

  • All chemistry efforts will be performed at the Abing () y don (UK) facility
  • All project work in Thane will be completed by the end of September 2013
  • Approximately 120 Thane-based employees will leave the company
  • Evotec will take a one-time impairment charge of up to € 4 m in Q3 2013

Growth driven by high-quality services

EVT Execute strategy 2013 3

Further improve gro profitability 3 oss margins and

Systematic, unbias comprehensive ap sed and pproach

"EVT Integrate & Innovate e" disease focus

All clinical p g ro ram significant data po mmes on track for oints in 2013/2014/2015

Clinical-stage pipeline

D
C
d
i
d
t
r
g
a
n
a
e
u		 P
(
S
f
h
i
)
t
t
t
t
a
r
n
e
r
a
r
o
p
a
r
n
e
r
s
p		 P
D
C		 P
h
h
I
a
s
e		 P
h
I
I
a
s
e		 P
h
I
I
I
a
s
e		 S
t
t
a
s
u
®
D
i
P
2
7
7
a
e
p
(
D
i
b
)
t
a
e
e
s		 T
E
V
A
/
A
d
d
(
2
0
0
)
7
n
r
o
m
e
a		 d
n
2
P
h
I
I
I
i
l
d
t
t
a
s
e
r
e
c
r
u
m
e
n
c
o
s
e
,
l
d
d
f
2
0
1
4
(
)
t
t
r
e
s
u
s
e
x
p
e
c
e
e
n
o
e
E
V
T
3
0
2
(
A
l
h
i
'
z
e
m
e
r
s
d
i
)
s
e
a
s
e		 R
h
(
2
0
1
1
)
o
c
e		 P
h
I
I
b,
l
t
t
d
a
s
e
r
e
s
s
e
p
e
c
e
u
x
l
2
0
1
5
(
)
e
a
r
y
e
1
0
0
E
V
T
i
s
e
r
e
s
(
)
D
i
e
p
r
e
s
s
o
n		 (
)
J
2
0
1
2
a
n
s
s
e
n		 2
0
1
2
f
P
t
d
i
D
t
t
a
r
n
e
r
e
n
e
c
s
a
r
o
,
/
(
)
P
h
I
I
d
i
2
0
1
3
2
0
1
4
a
s
e
r
n
g
e
u
E
V
T
2
0
1
(
I
i
)
n
s
o
m
n
a		 J
i
X
i
(
2
0
1
0
)
n
g
n		 I
A
i
l
2
0
1
3
l
i
d
n
p
r
a
p
p
r
o
v
a
r
e
c
e
v
e
f
C
D
E
l
i
i
l
t
r
o
m
o
c
o
m
m
e
n
c
e
c
n
c
a
t
i
l
r
a
s
S
t
i
o
m
a
o
p
r
m
(
A
l
)
c
r
o
m
e
g
a
y…		 A
i
(
2
0
1
2
)
s
p
r
e
o		 P
t
i
i
a
r
n
e
r
n
g
p
r
o
c
e
s
s
o
n
g
o
n
g
0
1
E
V
T
4
(
f
)
I
l
t
i
n
a
m
m
a
o
n		 C
(
)
b
2
0
1
2
o
n
a		 "G
"
f
i
d
r
e
e
n
p
a
s
s
r
e
c
e
v
e
r
o
m
C
G
h
i
t
n
e
s
e
o
e
r
n
m
e
n
v
V
i
a
r
o
u
s		 V
i
a
r
o
u
s		 S
l
l
i
i
l
d
i
t
t
t
e
v
e
r
a
c
n
c
a
s
a
r
s
e
x
p
e
c
e
n
2
0
1
3
/
2
0
1
4

First-in-class diabinto disease comp etes p pi eline – Exp g andin plications & new mechanisms

Diabetes and diabetic commplications pipeline overview

M
l
l
(
)
o
e
c
e
s
u		 I
d
i
i
t
n
c
a
o
n
(
h
i
)
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 N
t
e
x
i
l
t
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
®
D
i
P
2
7
7
a
e
p		 T
1
d
i
b
t
y
p
e
a
e
e
s
(
)
i
d
l
t
i
m
m
n
o
m
o
a
o
n
u
u		 nd
2
P
h
I
I
I
a
s
e
i
t
t
r
e
c
r
m
e
n
u
l
d
c
o
s
e		 F
i
l
P
h
n
a
a
s
e
I
I
I
d
t
a
a		 U
t
€
4
0
i
l
t
l
t
i
p
o
m
m
e
s
o
n
e
s,
r
o
y
a
e
s
;
€
t
t
i
l
k
t
5
0
0
p
o
e
n
a
m
a
r
e
a
p
p
r
o
m
x.
E
V
T
0
7
7		 T
T
1
1
d
d
2
d
d
i
i
b
b
t
t
y
p
e
a
n
a
e
e
s
(
b
t
l
l
t
i
)
e
a
c
e
r
e
g
e
n
e
r
a
o
n		 P
P
l
l
i
i
i
i
l
l
r
e-
c
n
c
a		 P
h
I
a
s
e		 €
6
6
f
f
h
h
i
i
h
h
i
i
h
h
t
t,
t
t
t
t
m
u
p
r
o
n
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
;
u
p
o
€
2
5
4
i
l
t
/
d
t
m
m
e
s
o
n
e
s
p
r
o
u
c
;
f
i
i
i
t
l
t
i
s
g
n
c
a
n
r
o
a
e
s
y
A
L
M		 T
1
d
2
d
i
b
t
y
p
e
a
n
a
e
e
s
(
b
l
l
i
)
t
t
e
a
c
e
r
e
g
e
n
e
r
a
o
n		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I
a
s
e		 €
2
f
h
i
h
i
h
t,
t
t
m
u
p
r
o
n
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
;
u
p
o
€
1
8
3
i
l
/
d
i
i
f
i
l
i
t
t
t
t
m
m
e
s
o
n
e
s
p
r
o
u
c
;
s
g
n
c
a
n
r
o
y
a
e
s
E
V
T
0
7
0		 T
1
d
2
d
i
b
t
y
p
e
a
n
a
e
e
s
(
)
b
t
l
l
t
i
e
a
c
e
r
e
g
e
n
e
r
a
o
n		 A
d
d
v
a
n
c
e
l
d
e
a		 P
D
C		 €
7
f
t,
h
i
h
i
h
t
t
m
u
p
r
o
n
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
;
u
p
o
€
f
2
3
7
i
l
t
i
i
i
t
l
t
i
m
m
e
s
o
n
e
s,
s
g
n
c
a
n
r
o
a
e
s
y
V
i
a
r
o
s
u
C
B
t
u
r
e
e
a		 T
1
d
2
d
i
b
t
p
e
a
n
a
e
e
s
y
(
b
l
l
i
)
t
t
e
a
c
e
r
e
g
e
n
e
r
a
o
n		 /
T
t
I
D
a
r
g
e
l
i
d
i
t
v
a
a
o
n		 N
D		 €
8
f
t,
h
i
h
i
h
t
t
m
p
r
o
n
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
m
e
n
s
p
o
u
y
;
u
\$
3
0
0
i
l
/
d
i
i
f
i
l
i
t
t
t
t
m
m
e
s
o
n
e
s
p
r
o
u
c
;
s
g
n
c
a
n
r
o
y
a
e
s
V
i
a
r
o
s
u
C
N
h
u
r
e
e
p
r
o
n		 C
h
i
k
i
d
r
o
n
c
n
e
y
d
i
s
e
a
s
e		 /
T
t
I
D
a
r
g
e
l
i
d
i
t
v
a
a
o
n		 P
h
a
r
m
a
h
i
t
p
a
r
n
e
r
s
p		 N
D

Alzheimer's diseasdrives CNS pipelin se late-stag pp y e opportunity ne

Neurology pipeline overvi ew

I
d
i
i
t
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
i
l
t
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
A
l
h
i
's
z
e
m
e
r
(
O
)
D
i
M
A
B
s
e
a
s
e
-		 P
h
I
I
b
a
s
e		 C
l
t
i
f
P
h
I
I,
o
m
p
e
o
n
o
a
s
e
P
h
I
I
I
t
t
a
s
e
s
a
r		 \$
\$
1
2
f
t,
t
8
2
0
m
u
p
r
o
n
u
p
o
m
f
i
l
t
i
i
i
t
l
t
i
m
e
s
o
n
e
s
s
g
n
c
a
n
r
o
a
e
s
;
y
(
2
)
D
i
N
R
B
e
p
r
e
s
s
o
n		 /
P
h
I
I
a
s
e
l
i
i
l
p
r
e-
c
n
c
a		 C
f
i
i
f
l
l
i
i
i
i
l
l
t
o
n
r
m
a
o
e
n
o
p
p
r
r
e-
c
c
n
n
c
c
a
a
t
d
/
P
h
I
I
t
t
s
u
y
a
s
e
s
a
r		 \$
\$
2
f
f
1
6
0
i
l
t
t,
t
t
m
u
u
p
p
r
r
o
o
n
n
u
p
o
m
m
e
s
o
n
e
s
;
i
i
f
i
t
l
t
i
s
g
n
c
a
n
r
o
y
a
e
s
I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 S
t
t
l
i
i
l
t
i
l
a
r
c
n
c
a
r
a
s		 M
i
l
t
l
t
i
e
s
o
n
e
s
;
r
o
y
a
e
s
H
i
's
t
t
u
n
n
g
o
n
D
i
s
e
a
s
e		 T
t
a
r
g
e
l
i
d
t
i
v
a
a
o
n		 N
A		 R
h
t
e
s
e
a
r
c
p
a
y
m
e
n
s
M
l
t
i
l
l
i
p
e
s
c
e
r
o
s
s
u		 /
B
M
B
F
d
i
l
d
u
n
s
c
o
s
e
P
h
a
r
m
a		 L
d
e
a
i
t
g
e
n
e
r
a
o
n		 L
d
t
t
e
a
s
a
s
u		 N
D

Strong portfolio an pain and inflamma nd p p artnerships for novel ation targets

Pain and inflammation pip peline overview

M
l
l
(
)
o
e
c
e
s
u		 I
d
i
i
t
n
c
a
o
n
(
h
i
)
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 N
t
e
x
i
l
t
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
E
V
T
4
0
1		 I
f
l
t
i
n
a
m
m
a
o
n
(
)
P
2
X
7
i
h
i
b
i
t
n
o
r		 P
h
I
/
I
I
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 U
t
€
6
0
i
l
t
l
t
i
p
o
m
m
e
s
o
n
e
s
;
r
o
y
a
e
s
V
i
a
r
o
u
s		 E
d
t
i
i
n
o
m
e
r
o
s
s		 P
l
i
i
l
r
e-
c
n
c
a		 P
l
i
i
l
r
e-
c
n
c
a
d
i
d
t
c
a
n
a
e		 €
1
2
f
t,
t
t
l
l
t
m
u
p
r
o
n
o
a
v
a
u
e
u
p
o
a
p
p
r
o
x.
€
8
0
5
l
t
i
m
r
o
a
e
s
;
y
V
i
a
r
o
u
s		 V
i
/
P
i
a
r
o
u
s
a
n		 P
l
l
i
i
i
i
l
l
r
e-
c
c
n
n
c
c
a
a		 P
h
I
t
t
a
s
e
s
a
r		 U
d
i
l
d
f
f
t,
t
h
t
i
l
t
n
s
c
o
s
e
u
u
p
p
r
r
o
o
n
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
;
m
e
s
o
n
e
s
;
l
t
i
r
o
a
e
s
y
V
i
a
r
o
s
u		 f
I
l
t
i
n
a
m
m
a
o
n		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I
t
t
a
s
e
s
a
r		 €
H
i
h
i
h
t
t
1
8
3
g
m
a
r
g
g
n
r
e
s
e
a
r
c
p
p
a
m
e
n
s
p
p
o
m
y
y
;
;
u
i
l
/
d
i
i
f
i
l
i
t
t
t
t
m
e
s
o
n
e
s
p
r
o
u
c
;
s
g
n
c
a
n
r
o
y
a
e
s
U
d
i
l
d
n
s
c
o
s
e		 /
V
i
P
i
a
r
o
s
a
n
u		 P
l
i
i
l
r
e-
c
n
c
a		 S
f
l
c
c
e
s
s
u
u
P
P
C
C
o		 R
h
t
i
l
t
l
t
i
e
s
e
a
r
c
p
a
m
e
n
s
m
e
s
o
n
e
s
r
o
a
e
s
y
;
;
y

BI alliance leads p pipeline of oncology targets

Oncology pipeline overvie w

(
)
M
l
l
o
e
c
u
e
s		 I
d
i
i
t
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
t
e
x
i
l
t
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
S
t
i
o
m
a
r
o
p
n
(
D
G
3
1
3
)
7		 /
A
l
N
E
T
c
r
o
m
e
g
a
y		 P
h
I
I
a
s
e
a		 P
h
I
I
d
t
a
s
e
a
a
i
l
n
a
c
r
o
m
e
g
a
y		 C
f
l
t
i
l
t
i
o
n
s
n
g
e
e
s
r
o
a
e
s
u
;
y
V
i
a
r
o
s
u		 V
i
a
r
o
s
u		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I,
a
s
e
F
i
i
t
r
s
n
m
a
n		 R
h
t
i
l
t
l
t
i
e
s
e
a
r
c
p
a
m
e
n
s
m
e
s
o
n
e
s
r
o
a
e
s
y
;
;
y
P
t
h
a
a
n
s
c
r
e
e
w
y		 C
b
l-
B
B
t
h
p
a
a
w
y		 P
l
l
i
i
i
i
l
l
r
e-
c
c
n
n
c
c
a
a		 P
h
a
r
m
a
h
i
t
p
a
r
n
e
r
s
p		 S
h
d
h
t
i
l
t
l
t
i
a
r
e
r
e
s
e
a
r
c
c
o
s
s
m
e
s
o
n
e
s
r
o
a
e
s
;
;
y
E
i
i
p
g
e
n
o
m
c
s
t
t
a
r
g
e
s		 V
i
a
r
o
u
s		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
a
r
m
a
h
i
t
p
a
r
n
e
r
s
p		 N
D

TargetKDM (Lysin e demethylase inhibitors)1)

Project overview

O
b
j
i
t
e
c
v
e		 D
l
i
l
f
d
i
d
i
i
i
h
i
b
i
d
t
t
t
t
e
e
o
p
a
n
n
q
e
p
p
a
o
r
m
o
s
c
o
e
r
a
n
o
p
m
s
e
n
o
r
s
a
n
v
u
u
v
b
i
k
f
l
i
d
t
d
K
D
M
i
o
m
a
r
e
r
s
o
r
a
a
e
s
n
c
a
n
c
e
r
v
T
l
t
a
r
g
e
c
a
s
s		 L
i
d
h
l
t
y
s
n
e
e
m
e
y
a
s
e
e
s
T
h
i
1
°
t
e
r
a
p
e
c
a
r
e
a
u		 O
i
l
b
d
i
d
t
t
t
t
p
m
a
c
a
n
c
e
r
y
p
e
e
o
e
e
e
r
m
n
e
S
d
t
t
t
a
r
a
e		 /
5
2
0
1
3
S
t
t
a
u
s		 f
P
l
i
i
l
T
t
l
i
d
t
i
d
h
i
t
i
d
t
i
i
t
i
r
e
-c
n
c
a
:
a
r
g
e
v
v
a
a
o
n
a
n
e
n
c
a
o
n
P
j
t
t
t
r
o
e
c
s
r
a
e
g
y		 F
b
d
d
d
i
t-
r
a
g
m
e
n
a
s
e
r
u
u
g
s
c
o
v
e
r
y
P
t
a
r
n
e
r
s		 J
i
E
l
i
h
K
k–
K
K
i
i
W
W
B
l
f
I
i
t
t
t
e
s
s
e
n
g
s
o
o
n
n
o
o
n
n
g
g
e
e
r
n
s
e
w
u
,
,
C
i
l
o
m
m
e
r
c
a		 S
h
d
h
i
l
l
i
t
t
t
a
r
e
r
e
s
e
a
r
c
c
o
s
s
m
e
s
o
n
e
s
r
o
y
a
e
s
;
,
,
i
h
h
E
E
t
t
t
p
a
r
n
e
r
n
g
r
o
u
g
v
o
e
c

TargetPGB (Peptid doglycan Biosynthesis)

Project overview

j
i
O
b
t
e
c
e
v		 I
d
i
f
i
i
f
l
i
b
i
i
h
i
h
i
b
i
l
l
l
l
h
i
t
t
t
t
t
t
t
t
e
n
c
a
o
n
o
n
o
v
e
e
a
n
o
c
a
n
c
e
w
a
s
y
n
e
s
s
T
l
t
a
r
g
e
c
a
s
s		 B
i
l
i
d
l
l
l
f
(
P
G
T
)
t
t
t
a
c
e
r
a
p
e
p
o
g
y
y
c
a
n
g
y
c
o
s
y
r
a
n
s
e
r
a
s
e
s
s
T
h
i
1
°
t
e
r
a
p
e
c
a
r
e
a
u		 S
M
h
i
i
l
l
i
i
h
l
(
M
R
S
A
)
t
t
t
t
e
c
n-
r
e
s
s
a
n
a
p
o
c
o
c
c
s
a
r
e
s
y
u
u
u
S
d
t
t
t
a
r
a
e		 /
5
2
0
1
3
S
t
t
a
s
u		 P
l
i
i
l
H
i
i
d
i
f
i
i
t
t
t
r
e
-c
n
c
a
:
e
n
n
c
a
o
n
P
j
t
t
t
r
o
e
c
s
r
a
e
g
y		 H
T
S
i
i
i
b
d
b
t
s
n
g
p
r
o
p
r
e
a
u
a
r
y
m
o
e
n
o
m
y
c
n-
a
s
e
p
r
o
e
A
d
i
t
c
a
e
m
c
p
a
r
n
e
r
s		 S
D
K
K
h
h
W
W
l
l
k
k
H
d
U
i
i
t
a
n
a
a
n
n
e
e
a
n
n
n
e
a
a
e
e
r,
r
a
r
a
r
n
e
r
s
u
z
v
v
y
,
C
i
l
o
m
m
e
r
c
a		 S
h
d
h
i
l
l
i
t
t
t
a
r
e
r
e
s
e
a
r
c
c
o
s
s
m
e
s
o
n
e
s
r
o
y
a
e
s
;
,
,
i
h
h
E
E
t
t
t
p
a
r
n
e
r
n
g
r
o
u
g
v
o
e
c

First-in-class prod even stronger port duct candidates and an tfolio of partnerships

EVT Innovate/Integrate st trategy 2013

programmes

Agenda

  • Highlights H1 2013
  • Strategy on innovation e efficiency
  • Financial performance e & outlook

Decline in revenuelow milestone revees due to expected enues in H1 2013

Revenues & gross margin H1

Clear investment f focus for first-in-class innovation

Overview R&D and SG&AH1

in € m

in € m

Investments in Cuaccelerate innovatre X and Target X p j ro ects tion efficiency strategy

Key financials H1 2013: Co ondensed consolidated income statement (IFRS)

H
1
2
0
1
2		 H
1
2
0
1
3
R
e
e
n
e
s
v
u		 4
2
0		 3
6
7
G
i
r
o
s
s
m
a
r
g
n		 3
5
2
%
%		 2
8
8
%
&
R
D
e
x
p
e
n
s
e
s
 3
9		 4
8
S
G
&
A
e
x
p
e
n
s
e
s
 8
0		 8
2
A
i
i
t
t
m
o
r
s
a
o
n
 1
2		 1
7
O
t
h
t
i
i
e
r
o
p
e
r
a
n
g
n
c
o
m
e

(
),
t
e
x
p
e
n
s
e
s
n
e		 0
3		 0
2
O
i
i
(
l
)
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 1
3		 (
4
4
)
(
)
N
i
l
t
e
n
c
o
m
e
o
s
s		 1
7		 (
)
4
6

Revenues excluding milestones, upfronts and licences up 6% on a like-forlike basis compared to the same period of the previous year

Op g erating and net for innovation andloss due to accelerated sp g endin d low milestone revenues

Q2 2013: Condensed cons olidated income statement

in € m

Q
2
2
0
1
2		 Q
2
2
0
1
3
R
e
v
e
n
u
e
s		 2
1
9		 1
9
6
G
i
r
o
s
s
m
a
r
g
n		 %
3
7
7		 3
1
1
%
R
&
D
e
p
e
n
s
e
s
x
 2
0		 5
2
S
G
&
A
e
p
e
n
s
e
s
x
 3
6		 4
3
A
t
i
t
i
m
o
r
s
a
o
n
 0
7		 0
8
O
O
(
)
h
h
i
t
t
e
e
r
r
o
o
p
p
n
c
o
m
e
e
e
x
x
p
p
e
e
n
n
s
s
e
e
s
s

,
t
n
e		 (
)
0
7
(
)
O
i
i
l
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 2
6		 (
)
1
7
i
(
)
N
l
t
e
n
c
o
m
e
o
s
s		 3
7		 (
)
1
7
  • Lower milestones in Q2 2013
  • Increased investment in Innovation R&D
  • Slightly higher SG&A gyg
  • Fair value adjustment earn out in Q2 2013: € 0 3 m expense 0.20.3 (Q2 2012: € 1.0 m income)

Others

New appointments1)

S
h
i
f
t
t
r
e
n
g
e
n
n
g
o
t
m
a
n
a
g
e
m
e
n
i
i
t
c
a
p
a
c
e
s		 D
A
d
i
H
d
E
i
i
V
i
P
i
d
H
d
f
N
l
&
C
t
t,
t
r
r
a
n
o
w
x
e
c
u
v
e
c
e
r
e
s
e
n
e
a
o
e
u
r
o
o
g
y
o
r
p
o
r
a
e

,
D
l
t
e
e
o
p
m
e
n
v
S
O
G
f
B
t
i
d
d
h
l,
l
b
l
H
d
H
R
a
s
a
n
a
e
r-
e
n
a
o
a
e
a
o
m
a
n
e
s
o
r
c
e
s
u
u
u
S
i
f
h
t
t
r
e
n
g
e
n
n
g
o
i
b
s
n
e
s
s
u
d
l
t
e
e
o
p
m
e
n
v
i
i
i
i
J
t
t
a
c
e
s
n
a
p
a
n
v		 O
(
)
M
h
i
k
h
t
i
V
i
P
i
d
t
B
i
D
l
t
J
a
s
a
o
a
n
a
s
c
e
e
r
e
s
e
n
s
n
e
s
s
e
e
o
p
m
e
n
a
p
a
n
u
v
R
&
D
d
a
y		 R
&
D
d
d
i
i
l
l
l
l
b
b
h
h
l
l
d
d
i
i
O
O
b
b
i
i
N
N
Y
Y
k
k
(
(
i
i
i
i
i
i
i
i
l
l
l
l
f
f
l
l
l
l
)
)
t
t
t
t
t
t
t
t
a
y
w
e
e
n
c
o
e
r
n
e
w
o
r
s
e
p
a
r
a
e
n
v
a
o
n
w
o
o
w

FY 2013 guidance confirmed

Business overview 2013

in € m

H
1
2
0
1
2		 H
1
2
0
1
3		 ∆
H
1
H
1
–		 F
Y
2
0
1
3
G
G
i
i
d
d
u
a
n
c
e		 F
Y
2
0
1
2
R
e
v
e
n
u
e
s		 4
2
0		 3
6
7
7		 1
3
%
-		 9
0
1
0
0
-		 8
7
3
O
i
l
t
t,
p
e
r
a
n
g
r
e
s
u
)
1
d
j
d
t
a
u
s
e		 0
6		 (
)
)
4
1		 I
d
m
p
r
o
e
v
2
0
1
2
o
v
e
r		 1
4
U
d
R
&
D
t
n
p
a
r
n
e
r
e
e
p
e
n
s
e
s
x		 (
3
9
)		 (
)
)
4
8		 2
3
%
+		 1
0
a
p
p
r
o
x		 (
)
8
3
L
i
i
d
i
i
d
d
t
t
q
u
y
a
p
e
r
o
-e
n		 3
4
5		 5
6
1
1		 5
%
+		 )
2
6
0
>		 6
4
2

Strong news flow to come

Outlook and next steps for r 2013 ff

Key milestones for 2013

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81 - 242 +49.(0).40.560 81 - 333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
AGM Information 2026
May 7
Interim / Quarterly Report 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Major Shareholding Notification 2026
May 5
View all filings →